ClinicalTrials.gg
DrugRead study by study

Tucatinib clinical trials

Also written Tukysa, ONT-380, ARRY-380 and Irbinitinib.

studies test it
55
open now
15
in phase 3
5
first study started
2008
ClinicalTrials.gov finds 72 studies for tucatinib. How that becomes 55 here

Every study that search finds has been read, to see whether and how it gives tucatinib. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count

  1. 72Found by its intervention search · See all 72 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 67 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. −1
    Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
  3. +2Give it under a name that search misses: a biosimilar’s code or a misspelling
  4. 73Give tucatinib to participants
  5. −6Observe patients on it, or give it outside a trial
  6. −1Compare another treatment with it
  7. −11Give it beside what is tested
  8. 55Test it: the count on this site

Get an email when these change. Save the tucatinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
17 Apr 2020 · TUKYSA · NDA 213411 (FDA, Drugs@FDA)
European Union
11 Feb 2021 · Tukysa · EMEA/H/C/005263 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Tucatinib
43
TUKYSA, ONT-380, ARRY-380
2
TUKYSA, ARRY-380, ONT-380
2
Tucatinib (ONT-380)
2

Brand

Tukysa
17

Development codes

ONT-380
8
ARRY-380
4
MK-7119
2
PF-07265792
1

Other names

Irbinitinib
2

Studies by the year they started

55 studies that test it; most in 2023 (12)

Studies that test tucatinib, by start year
YearStudies
20081
20101
20132
20141
20162
20173
20184
20194
20204
20218
20227
202312
20244
20262

By phase

A phase 1/2 study counts in both.

Phase 1
21
Phase 2
35
Phase 3
5
Phase 4
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 25 · Other 30

Seagen Inc. (11) · Seagen, a wholly owned subsidiary of Pfizer (6) · Pfizer (3) · Dana-Farber Cancer Institute (3) · Criterium, Inc. (2) · Memorial Sloan Kettering Cancer Center (2) · UNICANCER (2) · Institut Curie (2)

Often tested with

Tested in the same studies.

Trastuzumab (17) · Pertuzumab (5) · Capecitabine (4) · Trastuzumab deruxtecan (4) · Ado-Trastuzumab Emtansine (4) · Olaparib (3) · Pembrolizumab (3) · Atezolizumab (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Tucatinib is the comparator. A study of two new drugs counts under both.

  • 1Bizrolertinib · Hoffmann-La Roche · next primary completion May 2029
New treatments tested with it · 7 most studied

New when their studies opened, with tucatinib beside them; studies of each.

Reaching primary completion within a year · 10

Studies that test tucatinib.

Studies

Open first, then newest update. How each study uses tucatinib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 55

See all 55 studies that test tucatinib →

Behind its US label · 3 — the studies the FDA label of TUKYSA describes

From the Clinical Studies section of TUKYSA (2026-10), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 6 — no other medicine in its arm
Tested with established drugs · 16 — they are given beside it
Tested in a combination · 33 — another drug in the study is under test too

Showing 20 of 33. See all 33 →

Beside an established treatment under test · 2 — an approved drug, surgery or radiation is what the study tests

Tested with tucatinib: Capecitabine 2 · margetuximab 1

Beside a new treatment under test · 7 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with tucatinib: zanidatamab 2 · disitamab vedotin 1 · Mutant-selective PI3K-alpha H1047R Inhibitor OKI-219 1 · cinrebafusp alfa 1 · patritumab deruxtecan 1 · ALX148 1 · MicroRNA-10b Antagomir-Iron Oxide/Dextran-based Nanoparticle TTX-MC138 1

Beside supportive care · 1 — a supportive treatment or test is studied
One option of several · 1 — a test or a strategy chooses among drugs
As the comparator · 1 — what is tested is compared with tucatinib
Observed · 6 — patients on it are followed, or it is given outside a trial

Codes

What other systems call tucatinib · ClinicalTrials.gg INT001276

  • MeSH (NLM) C000705452tucatinibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 234248D0HHTUCATINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 2361285One source FDA
  • Wikidata Q25100690tucatinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C77896TucatinibOne source FDA
  • DrugBank DB11652One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion